AFPThe Centre has inked a Rs 1500 crore deal with Hyderabad-based vaccine maker Biological-E for 300 million COVID-19 vaccine doses.
The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.
After Bharat Biotech's Covaxin, this will be the second made-in-India vaccine.
The government is also in talks with foreign makers Pfizer and Moderna, who have insisted on an indemnity clause.
Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnson's COVID-19 shot annually, said on Tuesday it entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India.
Biological-E will run a clinical trial of Providence's vaccine in India and seek emergency use approval.
Besides Covaxin and Serum Institute of India's Covishield, Russia's Sputnik V will also soon be used in the country as the Modi government races to meet the target of administring one crore vaccinations a day by August.
The government has drawn criticism for a slow vaccine rollout even though India is one of the world's biggest manufacturers of doses.
The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.
After Bharat Biotech's Covaxin, this will be the second made-in-India vaccine.
The government is also in talks with foreign makers Pfizer and Moderna, who have insisted on an indemnity clause.
Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnson's COVID-19 shot annually, said on Tuesday it entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India.
Biological-E will run a clinical trial of Providence's vaccine in India and seek emergency use approval.
Besides Covaxin and Serum Institute of India's Covishield, Russia's Sputnik V will also soon be used in the country as the Modi government races to meet the target of administring one crore vaccinations a day by August.
The government has drawn criticism for a slow vaccine rollout even though India is one of the world's biggest manufacturers of doses.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.